scispace - formally typeset
P

Pao-Yen Lin

Researcher at Chang Gung University

Publications -  160
Citations -  5392

Pao-Yen Lin is an academic researcher from Chang Gung University. The author has contributed to research in topics: Randomized controlled trial & Major depressive disorder. The author has an hindex of 33, co-authored 159 publications receiving 4231 citations. Previous affiliations of Pao-Yen Lin include Memorial Hospital of South Bend & National Cheng Kung University.

Papers
More filters
Journal ArticleDOI

A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids.

TL;DR: Although the meta-analysis showed significant antidepressant efficacy of omega-3 PUFAs, it is still premature to validate this finding due to publication bias and heterogeneity.
Journal ArticleDOI

A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression.

TL;DR: These findings provide further support to the phospholipid hypothesis of depression and a rationale for using n-3 polyunsaturated fatty acids as an alternative treatment for depression, and future studies examining specific roles of DHA and EPA in different clusters of depressive symptoms are warranted.
Journal ArticleDOI

Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis

TL;DR: A meta-analysis of all the double-blind, placebo-controlled studies in patients with schizophrenia was performed to examine their efficacy on different symptom domains, the dose-response, the effects of concomitant antipsychotics, and their side effects, revealing that glycine, D-serine and sarcosine are better than D-cycloserine in improving the overall psychopathology.
Journal ArticleDOI

Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis.

TL;DR: The results provide significant evidence supporting the association of the s allele of 5-HTTLPR polymorphism with suicidal behavior in the psychiatric population, also with violent suicide, and support a role for decreased serotonin transporter function in the vulnerability to suicide in a select population.
Journal ArticleDOI

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.

TL;DR: Sarcosine was well tolerated and no significant side-effect was noted, and unlike patients treated with other antipsychotics, patients who received clozapine treatment exhibit no improvement by adding sarcosine or agonists at the NMDA-glycine site.